{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Praluent+%28Alirocumab%29", "query": { "intervention": "Praluent (Alirocumab)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 57, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Praluent+%28Alirocumab%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-02T15:21:29.865Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03510884", "title": "An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolaemia" ], "interventions": [ { "name": "Alirocumab SAR236553 (REGN727)", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Simvastatin", "type": "DRUG" }, { "name": "Pravastatin", "type": "DRUG" }, { "name": "Lovastatin", "type": "DRUG" }, { "name": "Fluvastatin", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Cholestyramine", "type": "DRUG" }, { "name": "Nicotinic acid", "type": "DRUG" }, { "name": "Fenofibrate", "type": "DRUG" }, { "name": "Omega-3 fatty acids", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "8 Years to 17 Years" }, "enrollment_count": 153, "start_date": "2018-05-31", "completion_date": "2022-08-05", "has_results": true, "last_update_posted_date": "2023-05-06", "last_synced_at": "2026-10-02T15:21:29.865Z", "location_count": 5, "location_summary": "Boca Raton, Florida • St Louis, Missouri • Charlotte, North Carolina + 2 more", "locations": [ { "city": "Boca Raton", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03510884" }, { "nct_id": "NCT02992301", "title": "Assessment of Atherosclerotic Plaque Characteristics Change by DCE-MRI With Alirocumab", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Atherosclerosis", "Hyperlipidemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Westside Medical Associates of Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2016-11", "completion_date": "2019-11", "has_results": false, "last_update_posted_date": "2019-04-26", "last_synced_at": "2026-10-02T15:21:29.865Z", "location_count": 1, "location_summary": "Beverly Hills, California", "locations": [ { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02992301" }, { "nct_id": "NCT01448239", "title": "Injection Site Tolerability, Safety, Pharmacokinetics and Pharmacodynamics Study After a Single Dose Subcutaneous Treatment of Alirocumab SAR236553 (REGN727)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "alirocumab SAR236553 (REGN727)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 24, "start_date": "2011-02", "completion_date": "2011-05", "has_results": false, "last_update_posted_date": "2013-06-28", "last_synced_at": "2026-10-02T15:21:29.865Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01448239" }, { "nct_id": "NCT01730040", "title": "Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 355, "start_date": "2012-10", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2015-08-31", "last_synced_at": "2026-10-02T15:21:29.865Z", "location_count": 56, "location_summary": "Mobile, Alabama • Chandler, Arizona • Tucson, Arizona + 53 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01730040" }, { "nct_id": "NCT07477704", "title": "A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 420, "start_date": "2026-06-17", "completion_date": "2027-02-23", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-02T15:21:29.865Z", "location_count": 34, "location_summary": "Anniston, Alabama • Cullman, Alabama • Anaheim, California + 30 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Cullman", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Walnut Creek", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07477704" }, { "nct_id": "NCT01730053", "title": "Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 305, "start_date": "2012-11-30", "completion_date": "2014-05-31", "has_results": true, "last_update_posted_date": "2020-04-07", "last_synced_at": "2026-10-02T15:21:29.865Z", "location_count": 54, "location_summary": "Chandler, Arizona • Tucson, Arizona • Anaheim, California + 51 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fair Oaks", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01730053" }, { "nct_id": "NCT01644175", "title": "Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Placebo (for alirocumab)", "type": "DRUG" }, { "name": "Alirocumab", "type": "DRUG" }, { "name": "Lipid-Modifying Therapy (LMT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 316, "start_date": "2012-07", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2015-11-06", "last_synced_at": "2026-10-02T15:21:29.865Z", "location_count": 76, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 68 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01644175" }, { "nct_id": "NCT02957682", "title": "Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Praluent (Alirocumab)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "40 Years to 85 Years" }, "enrollment_count": 2176, "start_date": "2016-11-02", "completion_date": "2020-03-05", "has_results": true, "last_update_posted_date": "2021-05-07", "last_synced_at": "2026-10-02T15:21:29.865Z", "location_count": 73, "location_summary": "Auburn, Alabama • Birmingham, Alabama • Mobile, Alabama + 63 more", "locations": [ { "city": "Auburn", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Gatos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02957682" }, { "nct_id": "NCT04781322", "title": "Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Alcohol Associated Liver Disease", "Heavy Drinking Behavior" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Institute on Alcohol Abuse and Alcoholism (NIAAA)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "21 Years to 65 Years" }, "enrollment_count": 100, "start_date": "2021-10-19", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-10-02T15:21:29.865Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04781322" }, { "nct_id": "NCT04790513", "title": "Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia", "Cardiovascular Diseases" ], "interventions": [ { "name": "lerodalcibep", "type": "BIOLOGICAL" }, { "name": "evolocumab", "type": "BIOLOGICAL" }, { "name": "alirocumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "LIB Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 204, "start_date": "2021-04-22", "completion_date": "2022-12-31", "has_results": false, "last_update_posted_date": "2023-03-29", "last_synced_at": "2026-10-02T15:21:29.865Z", "location_count": 3, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04790513" } ] }